| Bioactivity | AT-007 is an orally active central nervous system (CNS) penetrant Aldose Reductase inhibitor for treatment of Galactosemia with an IC50 value of 100 pM. AT-007 reduces toxic galactitol levels and prevents disease complications in GALT deficiency rats[1][2]. | ||||||||||||
| Target | IC50: 100 pM (Aldose Reductase) | ||||||||||||
| In Vivo | AT-007 显着降低了 GALT 缺失大鼠的脏器组织（肝，脑和血浆）中半乳糖醇水平，但没有增加半乳糖或 Gal1P 的水平[2]。 | ||||||||||||
| Name | AT-007 | ||||||||||||
| CAS | 2170729-29-8 | ||||||||||||
| Formula | C17H10F3N3O3S2 | ||||||||||||
| Molar Mass | 425.40 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Maeve Conneighton, et al. Applied Therapeutics Announces Initiation of Phase 1/2 Study of AT-007 in Galactosemia. [2]. UNITED STATES SECURITIES AND EXCHANGE COMMISSION. APPLIED THERAPEUTICS, INC. |
AT-007
CAS: 2170729-29-8 F: C17H10F3N3O3S2 W: 425.40
AT-007 is an orally active central nervous system (CNS) penetrant Aldose Reductase inhibitor for treatment of Galactosem
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.